Bank Of Montreal Heron Therapeutics, Inc. Transaction History

Bank Of Montreal

$192 Billion
Q1 2025

A detailed history of Bank Of Montreal transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Bank Of Montreal holds 26,101 shares of HRTX stock, worth $49,591. This represents 0.0% of its overall portfolio holdings.

Number of Shares

26,101

Holding current value

$49,591

% of portfolio

0.0%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$1.47 - $2.55 $38,368 - $66,557	26,101 New	26,101 $57,000
Q3 2024 Nov 13, 2024	BUY	$1.73 - $3.67 $43,585 - $92,461	25,194 New	25,194 $50,000
Q2 2022 Aug 11, 2022	SELL	$2.3 - $6.29 $101,015 - $276,256	-43,920 Reduced 43.66%	56,680 $192,000
Q1 2022 May 12, 2022	SELL	$4.63 - $9.94 $284,883 - $611,608	-61,530 Reduced 37.95%	100,600 $574,000
Q4 2021 Feb 11, 2022	SELL	$8.35 - $12.6 $17,034 - $25,704	-2,040 Reduced 1.24%	162,130 $1.51 Million
Q3 2021 Nov 12, 2021	SELL	$10.13 - $15.0 $1.88 Million - $2.79 Million	-185,939 Reduced 53.11%	164,170 $1.88 Million
Q2 2021 Aug 12, 2021	BUY	$13.27 - $18.48 $4.65 Million - $6.47 Million	350,109 New	350,109 $5.56 Million

Others Institutions Holding HRTX

# of Institutions

182

Shares Held

125M

Call Options Held

847K

Put Options Held

47.7K

Rubric Capital Management LP New York, NY

26.7M
Shares

$50.8 Million
1.68% of portfolio
Black Rock Inc. New York, NY

8.33M
Shares

$15.8 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

8.23M
Shares

$15.6 Million
0.0% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

7.85M
Shares

$14.9 Million
0.03% of portfolio
Velan Capital Investment Management LP Alpharetta, GA

6.99M
Shares

$13.3 Million
26.51% of portfolio

View Full List

About HERON THERAPEUTICS, INC.

Ticker HRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,774,000
Market Cap $226M
Description
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...

More about HRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.

Account